Communiqués AstraZeneca PLC

Actions

AZN

GB0009895292

Produits pharmaceutiques

Marché Fermé - London S.E. Autres places de cotation 17:35:22 16/05/2025			Varia. 5j.	Varia. 1 janv.
10 330,00 ^GBX	+1,85 %		+0,88 %	-1,32 %

16/05	Les développeurs de médicaments amaigrissants se bousculent pour exploiter un marché lucratif alors que la concurrence s'intensifie.	RE
16/05	Les actions britanniques prolongent leur progression et devraient terminer la semaine en hausse grâce à l'optimisme commercial	RE

Communiqués

Appeals Court Rejects AstraZeneca's Challenge To IRA Negotiation Program	16/05	AQ
Innate Pharma Highlights ANKET Abstracts Selected for the EHA 2025 Congress	16/05	AQ
University of Glasgow: Professor Anthony Chalmers to co-lead new arm of international glioblastoma trial	14/05	AQ
Novel breast cancer treatment approach significantly enhances survival	13/05	AQ
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025	13/05	BU
AstraZeneca : to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025	13/05	PU
World-first approval supports AstraZeneca's sustainability goals	13/05	AQ
AstraZeneca : Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential	12/05	PU
AstraZeneca : Imfinzi improved DFS in early bladder cancer	09/05	PU
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial	09/05	BU
My Green Lab Launches ACT Ecolabel 2.0: Setting the Global Standard for Sustainable Laboratory Products	08/05	AQ
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11	07/05	BU
AstraZeneca : Enhertu followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial	07/05	PU
AstraZeneca : Enhertu improved pCR in early-stage breast cancer	07/05	PU
AstraZeneca : Calquence combination approved in EU for 1L MCL	06/05	PU
BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma	02/05	BU
AstraZeneca : Breztri met primary endpoints in Ph3 asthma trials	02/05	PU
Astrazeneca: Q1 Earnings Snapshot	29/04	AQ
AstraZeneca : Q1 2025 results announcement (Q1 2025 results announcement)	29/04	PU
AstraZeneca : Q1 2025 results presentation (Q1 2025 results presentation)	29/04	PU
AstraZeneca : Q1 2025 results clinical trials appendix (Q1 2025 results clinical trials appendix)	29/04	PU
AstraZeneca : Fixed-duration Calquence recommended in EU for CLL	29/04	PU
AstraZeneca : Update on CAPItello-280 Phase III trial	29/04	PU
AstraZeneca's Q1 2025 Financial Results	29/04	BU
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR	28/04	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

ASTRAZENECA : résultats supérieurs aux attentes au premier trimestre ; perspectives confirmées

Le 29 avril 2025 à 18:20

AstraZeneca enregistre une hausse de ses bénéfices grâce à ses médicaments contre le diabète et le cancer

Le 29 avril 2025 à 11:46